Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZBIO vs VERA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZBIO Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 3–4 Matrix Metrics)

ZBIO Overall Winner 6-Pillar Tally: ZBIO 2 – 2 VERA (2 Tie) Matrix Metrics: ZBIO 3 – 4 VERA

As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) is the stronger overall head-to-head candidate over Vera Therapeutics, Inc. (VERA) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas VERA carries 45.9/100 (HOLD) at $26.97 (N/M Forward P/E, -4160.1% operating margin).

  • Growth vs. Quality Trade-Off: ZBIO earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. VERA 45.9/100 HOLD) and 1.16β · 59% Vol risk profile, whereas VERA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile VERA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZBIO vs VERA
ZBIO NASDAQ Head-to-Head Winner
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.16β · 59% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.2%) with fading momentum, RSI 49
RSI-14: 49.0 · SMA20: $27.99 · SMA50: $28.48
VERA NASDAQ
Vera Therapeutics, Inc. Class A Common Stock
Pharmaceutical Preparations
$26.97
-4.02% 1D
Market Cap $2.1B
TTM Revenue $10M
Forward P/E N/M
Beta / 30D Vol 1.11β · 57% Vol
Unified Composite Score
45.9 / 100 HOLD
Tech 32.0 Fund 51.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.0%), weak momentum, RSI 39
RSI-14: 38.7 · SMA20: $29.87 · SMA50: $30.93

6-Pillar Scorecard Institutional Category Breakdown (ZBIO 2 – 2 VERA)

Columns: Metric · ZBIO · VERA
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale VERA
Revenue Growth (YoY) -100.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M $10M
Market Cap $1.9B $2.1B
3. Profitability & Quality VERA
Gross Margin N/A 67.9%
Operating Margin -2747.5% -4160.1%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -265.1% -113.5%
4. Balance Sheet & Cash Flow ZBIO
Cash Generation (TTM) -$273M -$377M
Cash Flow Margin N/A N/A
Net Cash / Leverage $177M Net Cash $21M Net Debt (0.23x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZBIO
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 95.3% (12th %ile) 108.9% (68th %ile)
Put/Call OI Skew N/A 0.02x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Distribution DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZBIO (3) vs VERA (4)
Institutional Metric ZBIO VERA Criterion Row Edge
Market Capitalization
Scale
$1.9B $2.1B Larger Scale VERA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% +0.0% Higher Growth VERA
Operating Margin (TTM)
Profitability
-2747.5% -4160.1% Higher Margin ZBIO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-265.1% -113.5% Higher ROE VERA
52-Week Range Position
Momentum
46% ($14–$45) 2% ($26–$56) Stronger Trend ZBIO
Beta / 30D Volatility
Risk Regime
1.16β · 59% Vol 1.11β · 57% Vol Lower Realized Risk VERA
Unified Institutional Score
Composite Signal
49.4 / 100 (HOLD) 45.9 / 100 (HOLD) Higher Composite ZBIO
Trailing 12M Revenue (USD)
Operating Scale
$11M $10M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 67.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$273M ($177M Net Cash) -$377M ($21M Net Debt (0.23x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZBIO +15.7 pp
ZBIO: +12.44% · VERA: -3.26%
3M Horizon ZBIO +3.98 pp
ZBIO: -12.47% · VERA: -16.45%
6M Horizon ZBIO +86.65 pp
ZBIO: +65.17% · VERA: -21.48%
1Y Horizon VERA +16.75 pp
ZBIO: -21.68% · VERA: -4.93%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZBIO vs VERA. Trailing 12-month operating profitability (ZBIO -2747.5% vs VERA -4160.1%) and valuation multiples (ZBIO N/M vs VERA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ZBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin-2747.5%
ROE / Fwd P/E-265.1% · N/M
VERA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$10M
Gross Margin67.9%
Op. Margin-4160.1%
ROE / Fwd P/E-113.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZBIO CONSOLIDATION
58d in phase · OBV ACCUMULATION
Current IV 95.3%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ZBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VERA BREAKDOWN
98d in phase · OBV DISTRIBUTION
Current IV 108.9%
IV Percentile 68th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact VERA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VERA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and -4160.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ZBIO vs VERA Key Questions & Quantitative Answers

As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) is the stronger overall head-to-head candidate over Vera Therapeutics, Inc. (VERA) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas VERA carries 45.9/100 (HOLD) at $26.97 (N/M Forward P/E, -4160.1% operating margin). Growth vs. Quality Trade-Off: ZBIO earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. VERA 45.9/100 HOLD) and 1.16β · 59% Vol risk profile, whereas VERA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile VERA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VERA leads the Growth & Scale pillar: ZBIO posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin), compared with VERA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $10M TTM revenue (67.9% gross margin, -4160.1% operating margin). On trailing 12-month operating scale, ZBIO generates $11M in USD-normalized revenue versus $10M for VERA. In operating R&D and SG&A reinvestment, ZBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VERA.

ZBIO and VERA trade at balanced relative valuation multiples. ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VERA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZBIO (-265.1% ROE) versus VERA (-113.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ZBIO carries 95.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk). By comparison, VERA carries 108.9% implied volatility (68th %ile, Elevated (60th–80th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.11β · 57% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.